Vascular endothelial growth factor (VEGF)-directed therapies, including anti-VEGF receptor (anti-VEGFr) TKIs became the new standard of care in 2005 following enhanced understanding of RCC biology. This evidence concerns the gene KDR and renal cell adenocarcinoma.